Otsuka Australia Pharmaceutical Pty Ltd Opens in Australia
News Jan 29, 2015
Otsuka Pharmaceutical Co., Ltd. has established a direct presence in Australia. A new office has been opened in Sydney to bring innovative new medicines to patients in Australia and as a foundation on which to build a larger, long-term presence in Australia and elsewhere in Oceania.
Otsuka is committed to the development of innovative new drugs for central nervous system disorders such as schizophrenia, depression and Alzheimer’s disease, areas where patients in Australia and elsewhere await better treatments. There are an estimated 285,000 people in Australia with schizophrenia, one million with depression and 298,000 with dementia, a significant number of whom have dementia of the Alzheimer’s type.
The Australian drug market has experienced single-digit percentage growth in the past several years and was estimated at approximately $13 billion (JPY 1.1 trillion or USD 13.6 billion) in 2012, placing it 12th in size in the world.
Otsuka Australia Pharmaceutical’s recently appointed managing director Kazushi Takemoto commented: “Otsuka is pleased and honoured to be a participant in the Australian healthcare sector. We will strive to make a positive contribution with our products in areas of critical, unmet patient need. Our opening in Australia, which is Otsuka’s 27th affiliate outside Japan, is an important milestone for Otsuka as the company continues to expand and fulfil its aim to help ease the burden of diseases on people around the globe.”
University of Wisconsin–Madison Professor of Chemistry Shannon Stahl has received the Steenbock Professorship in Chemical Sciences. In addition to advancing the fundamental science in this area, Stahl has been involved in numerous industrial collaborations that have led to practical applications, including target applications relevant to pharmaceutical synthesis.READ MORE